Rare Diseases Report 2022

The broad and challenging – but promising – landscape of peripheral neuropathy


 

Therapeutic options

There are no FDA-approved treatments for CSPN, as most treatments are geared toward neuropathic pain management, rehabilitation, and supportive care.68 Due to a lack of research and data regarding these types of peripheral neuropathies, various studies suggest different first-line therapies. For example, anticonvulsants (pregabalin, gabapentin), antidepressants (duloxetine), and opioid-like compounds (tramadol) are all threapy options to treat DPN.3

Adequate data are lacking to support the efficacy of immunosuppressive therapy in CSPN.

Pages

Recommended Reading

AAP guidance helps distinguish bleeding disorders from abuse
MDedge Family Medicine
Uncombable hair syndrome: One gene, variants responsible for many cases
MDedge Family Medicine
Shift in child hospice care is a lifeline for parents seeking a measure of comfort and hope
MDedge Family Medicine
Increasing primary care doctors’ knowledge of IPF could speed up diagnoses, suggests white paper
MDedge Family Medicine
ALS drug gets FDA panel thumbs-up after rare second look
MDedge Family Medicine
Myasthenia gravis: Finding strength in treatment options
MDedge Family Medicine
Lasker awardee pioneered prenatal DNA testing
MDedge Family Medicine
IVIG proves effective for dermatomyositis in phase 3 trial
MDedge Family Medicine
With sleuth work, pediatricians can identify genetic disorders
MDedge Family Medicine
Combination of energy-based treatments found to improve Becker’s nevi
MDedge Family Medicine